Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Darifenacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.98 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.98 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | DRD2 | P14416 | 1/20 | 0.98 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | HRH2 | P25021 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.98 |
| ▸ | HTR2B | P41595 | 1/20 | 0.98 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Darifenacin SCHEMBL5085916 | 1.00 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL1318587 | 1.00 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL29519864 | 1.00 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL2774455 | 0.99 | CHRM5 (1.00) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL56574 | 0.99 | CHRM5 (1.00) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL113331 | 0.99 | CHRM5 (1.00) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL31257801 | 0.99 | CHRM5 (1.00) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL1023445 | 0.98 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL3662174 | 0.98 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL138745 | 0.98 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 386 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106420647-B | A kind of sustained release preparation and preparation method thereof containing darifenacin hydrobromide | 山东创新药物研发有限公司 | 2019-11-22 | — | — | CN | claimed |
| CN-107721955-B | Darifenacin intermediate 2, the novel preparation method of 3- dihydro -5- benzofuranacetic acid | 内蒙古京东药业有限公司 | 2019-10-11 | — | — | CN | claimed |
| US-20190125734-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | NANOEGG RESEARCH LABORATORIES, INC. (JP) | 2019-05-02 | — | — | US | claimed |
| EP-3456353-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | Nanoegg Research Laboratories, Inc. (JP) | 2019-03-20 | — | — | EP | claimed |
| CN-107721954-A | The novel preparation method of the benzofuranacetic acid of 2,3 dihydro of darifenacin intermediate 5 | 内蒙古京东药业有限公司 | 2018-02-23 | — | — | CN | claimed |
| CN-107721955-A | The novel preparation method of the benzofuranacetic acid of 2,3 dihydro of darifenacin intermediate 5 | 内蒙古京东药业有限公司 | 2018-02-23 | — | — | CN | claimed |
| US-20170313687-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | NEUROSOLIS INC (US) | 2017-11-02 | — | — | US | claimed |
| CN-106420647-A | Sustained-release preparation containing darifenacin hydrobromide and preparation of sustained-release preparation | 山东创新药物研发有限公司 | 2017-02-22 | — | — | CN | claimed |
| US-20150099765-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | NEUROSOLIS INC (US) | 2015-04-09 | — | — | US | claimed |
| CN-102018658-B | Controlled release preparation and preparation method thereof | ZHONG SHUGUANG | 2014-03-12 | — | — | CN | claimed |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-23 | — | — | US | claimed |
| US-20070197630-A1 | Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2007-08-23 | — | — | US | claimed |
| WO-2007076158-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | claimed |
| WO-2007076159-A2 | PURE DARIFENACIN HYDROBROMIDE SUBSTANTIALLY FREE OF OXIDIZED DARIFENACIN AND SALTS THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | claimed |
| WO-2007076157-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | claimed |
| US-20060188554-A1 | Transdermal absorption preparation | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | claimed |
| EP-1652523-A1 | TRANSDERMAL ABSORPTION PREPARATION | Kyorin Pharmaceutical Co., Ltd. (JP) | 2006-05-03 | — | — | EP | claimed |
| EP-1245231-B1 | Pharmaceutical formulations containing darifenacin | NOVARTIS INT PHARM LTD (BM) | 2004-06-16 | — | — | EP | claimed |
| EP-1245231-A2 | Pharmaceutical formulations containing darifenacin | Pfizer Research and Development Company, N.V./S.A. (IE) | 2002-10-02 | — | — | EP | claimed |
| US-6106864-A | GASTROINTESTINAL DISORDERS | PFIZER INC. (US) | 2000-08-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125734-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | CHRM3, ACHE, CHRNB1 | CHRM3 1/4885CHRM2 5/4885CHRM5 7/4885 |
| US-20150099765-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | CHRM3, ACHE, CHRM4 | CHRM3 1/4885CHRM2 6/4885CHRM5 4/4885 |
| US-20070197630-A1 | Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof | OPRL1, OPRK1, OPRD1 | CHRM3 87/4885CHRM2 140/4885CHRM5 152/4885 |
| US-20170313687-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | CHRM3, ACHE, CHRM4 | CHRM3 1/4885CHRM2 6/4885CHRM5 4/4885 |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | CHRM3 69/4885CHRM2 166/4885CHRM5 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.